This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Ranked Momentum Stocks to Buy for November 6th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 6th.
The Zacks Analyst Blog Highlights: Facebook, JPMorgan Chase, Royal Dutch Shell, Starbucks and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, JPMorgan Chase, Royal Dutch Shell, Starbucks and Celgene
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Biotech ETFs in Focus on Impressive Q3 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
ImmunoGen (IMGN) Q3 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
Top Stock Reports for Facebook, JPMorgan & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), JPMorgan Chase (JPM) and Royal Dutch Shell (RDS.A).
Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Although Agios (AGIO) betters loss estimates in Q3, its revenues lag the same. The company's wholly owned leukemia drug Tibsovo sees a rise in sales sequentially.
Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise
by Zacks Equity Research
Celgene (CELG) beats on earnings and revenues in the third quarter of 2019 on strong performance from Otezla and Revlimid.
Bristol-Myers' (BMY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the third quarter, primarily on robust sales of Eliquis and Sprycel.
Celgene (CELG) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Celgene (CELG) delivered earnings and revenue surprises of 9.52% and 1.72%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Beats on Q3 Earnings, Ends Neuroscience R&D
by Zacks Equity Research
Amgen (AMGN) posts encouraging third-quarter 2019 results. It raises its previously issued sales guidance slightly while increasing the earnings range significantly.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on third-quarter sales.
Why the Earnings Surprise Streak Could Continue for Celgene (CELG)
by Zacks Equity Research
Celgene (CELG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Celgene (CELG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Celgene (CELG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Factors Setting the Tone for Celgene (CELG) Q3 Earnings
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Alexion to Buy Achillion for $930M, Strengthen PNH Franchise
by Zacks Equity Research
Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.
Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Celgene (CELG) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Celgene (CELG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas Inks Deal for Gene Editing Neurological Disease Drugs
by Zacks Equity Research
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Geron Starts Enrollment in Phase III MDS Study on Imetelstat
by Zacks Equity Research
Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.
Why Alexion is a Hot Takeover Target in the Biotech Sector
by Zacks Equity Research
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.
Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study
by Zacks Equity Research
Agios' (AGIO) Tibsovo improves progression free survival and reduces risk of disease progression or death in a phase III study in previously treated patients with IDH1 mutant cholangiocarcinoma.